Case Report

A Case Report of Acute Necrotizing Pancreatitis after COVID-19 Infection

Amir Mohammad Salehi1, Hossain Salehi2, Maryam Hasanzarrini3, Ensiyeh Jenabi4, and Aida Alizamir5

1School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2Gastroenterology Ward, Farheekhtegan Hospital, Islamic Azad University of Medical Sciences, Tehran, Iran
3Clinical Research Development Unit of Shahid Beheshty Hospital, Hamadan University of Medical Science, Hamadan, Iran
4Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
5Department of Pathology, School of Medicine, Fatemieh Hospital, Hamadan University of Medical Sciences, Hamadan, Iran

Correspondence should be addressed to Maryam Hasanzarrini; m.hasanzarrini@umsha.ac.ir

Received 24 March 2022; Revised 21 June 2022; Accepted 29 June 2022; Published 29 July 2022

Copyright © 2022 Amir Mohammad Salehi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Coronavirus 2019 (COVID-19), which is associated with many systemic inflammatory reactions and high morbidity and mortality rates, became a serious public health problem [1]. Although respiratory symptoms, including fever, dry cough, and shortness of breath, are the most common, gastrointestinal (GI) manifestations of COVID-19 are also increasingly recognized, with diarrhea being the most common manifestations of GI [2, 3].

Acute pancreatitis (AP) is a common disease, being the gastrointestinal disease most frequently requiring acute hospitalization [4]. Viral infections are the most common cause of acute pancreatitis. Other common causes are gallstones and alcohol abuse [5]. Multiple kinds of viruses including cytomegalovirus, Coxsackie B virus, Hepatitis A, B (Hep A, B), echovirus, Epstein–Barr virus, enterovirus, and human immunodeficiency virus (HIV) are known to cause AP [6]. With the advent of the COVID-19 epidemic, several cases of AP have been reported following infection with SARS-CoV-2. Herein, we report a case of AP with recently diagnosed COVID-19 infection without other risk factors for pancreatitis.

2. Case Presentation

A 38-year-old male with a chief complaint of nausea and severe epigastric pain with radiation to the back area was referred to the emergency room in Hamadan hospital. The patient was admitted to the hospital one week ago due to COVID-19 pneumonia with significant lung involvement (85% O2 saturation (Sat)) (Figure 1), so medical therapy with remdesivir (200 mg stat dose and then 100 mg Q12 hr) and dexamethasone (8 mg Q12 hr) was received just in hospital admission. The patient during hospital admission improved and was discharged without any complications and
medications, but one week after discharge from the hospital, he suddenly developed severe epigastric pain that radiated to the back area and nausea, so he has referred to the hospital again.

Past and personal history was normal. In the physical exam, the temperature was 38°C, respiratory rate (RR) 30/min, heart rate (HR) 115/min, blood pressure (BP) 95/65 mm Hg, 95Sat, the mucosa was dry, jugular venous pressure was normal, and no lymphadenopathy and thyromegaly, but in the chest, examination decreased breathing sound was heard. In the abdominal examination, generalized tenderness and distention and one area of ecchymosis in the left flank were seen (Figure 2). So, with the impression of pancreatitis, he was admitted and some workup was performed (Table 1).

Sonography showed severe interstitial pancreatitis with suspicion of necrotizing pancreatitis, so a spiral abdominal CT scan with the pancreatic protocol was performed favoring severe necrotizing pancreatitis (>30%) peripancreatic fluid accumulation (Figure 3). Fluid therapy with ringer lactate and antibiotic therapy (meropenem 500mg Q12h) was started, but the patient gradually developed a decreased level of consciousness and shock state and decreased O2 saturation. We did not have the opportunity for surgery to resect the necrotic tissues because the patient was in shock and did not respond despite supportive treatment, and the patient’s condition did not stabilize. The patient underwent mechanical ventilation and supportive care, but his condition deteriorated and expired after one day.

3. Discussion

AP is an acute inflammatory disease of the pancreas associated with high morbidity. Vomiting, nausea, and abdominal pain are common presentations of acute pancreatitis. It can be diagnosed by the presence of epigastric pain and tenderness to palpitation and abnormal increase of pancreatic enzymes (amylase or lipase) more than the three-time above the normal limit and/or imaging criteria (computed tomography, magnetic resonance imaging, and ultrasound) [7]. In our patient, AP presented with epigastric pain and nausea, and laboratory findings and imaging confirmed the diagnosis of AP. We were also able to exclude potential causes of AP, including alcoholism, drugs, hypertriglycerideridemia, hypercalcemia, Hep B and HIV infection, previous attacks or family history, and trauma, based on the patient’s history and tests.
Previously, Müller et al. isolated the SARS-CoV-2 nucleocapsid protein in beta cells and pancreatic exocrine cells in postmortem patients and found that SARS-CoV-2 could infect and proliferate in the pancreatic islets of the Langhans Islands and cause infection-related diabetes [8]. Although ACE2 and TMPRSS2 receptors, which are involved in virus binding and penetration, express more in pancreatic outlet cells than in pancreatic islet cells [9], for SARS-CoV-2, it is unclear whether tissue damage leading to AP occurs as a result of direct SARS-CoV-2 infection [10] or as a result of systemic multiple organ dysfunction syndrome (MODS) with increased levels of lipase which leads to the breakdown of triacylglycerols in adipose tissue cells and the formation of cytokine storms as a result of the toxic effect of unsaturated fatty acids on mitochondria [11] or following coagulation cascade activation caused by active inflammatory process due to SARS-CoV-2 infection. In this case, AP is associated with increased fibrinolysis resulting in higher levels of D-dimers [12].

The patient’s condition after an AP attack is directly related to the severity of the pancreatitis SIRS reaction. One of the scaling systems for the severity of pancreatitis is the Ranson scoring system, which is clinically efficient and useful [6]. It is evaluated using clinical and laboratory variables at the time of patient referral to the hospital. Five variables are measured at admission (age, WBC count, glucose, LDH, and AST) and six variables are measured within 48 hours (Hct drop, BUN increase, calcium, arterial pO2, base deficit, and fluid sequestration). A Ranson score of 0 or 1 predicts that complications will not develop and that mortality will be negligible [13]. A score of 3 or greater predicts severe AP and possible mortality [13]. In our patient, there were 5 variables of Ranson’s criteria (Table 2). It should be noted that serum amylase or lipase levels are only indicative of acinar cell damage and have nothing to do with the severity of pancreatitis or the likelihood of complications [14].

CT scan is the gold standard for definitive diagnosis of AP and also provides prognostic information to the physician. Baltazar et al. developed a grading system based on CT scan findings that included 5 grades: A (normal pancreas), B (enlargement of pancreas), C (inflammatory changes in pancreas and peripancreatic fat), D (ill-defined single peripancreatic fluid collection), and E (two or more poorly defined peripancreatic fluid collections), that our patient was in grade E [6]. It is important to understand that the severity of AP is not fixed. Therefore, a CT scan at any point in time does not accurately reflect the severity of the disease at another point in time, and in some cases, such as AP caused by SIRS, a series of CT scans are needed to control and monitor the course of the disease [15].

To reduce pancreatic secretion, discontinue oral feeding until pain and tenderness resolve and serum amylase and white blood cell count (WBC) return to normal. In severe cases such as our patient, several liters of the isotonic solution are needed to resuscitate the patient, so maintaining adequate tissue perfusion by monitoring hemodynamic parameters and maintaining adequate intravascular volume is very important. Therefore, electrolytes and blood glucose need direct control. Various studies have also shown that all pharmacological efforts to reduce pancreatic secretion, including anticholinergic drugs, somatostatin analogs, antacids, and aprotinin, have no significant benefit [16, 17].

In acute pancreatitis, respiratory function is carefully monitored by pulse oximetry because fluid accumulation within the pleural space and atelectasis interferes with the rise of the respiratory diaphragm. In some cases, the use of a ventilator is also required [6].

**Data Availability**

Access to data is possible with permission from the responsible author.

**Ethical Approval**

This study was approved by the Ethics Committee of the Hamadan University of Medical Science. This study was conducted in accordance with the Declaration of Helsinki.
Consent
The patient’s legal representative has given permission for the publication of this report and the accompanying images.

Conflicts of Interest
The authors declare they have no conflicts of interest.

References
[1] A. M. Salehi, H. Salehi, H. A. Mohammadi, and J. Afsar, "SARS-CoV-2 and subacute thyroiditis: a case report and literature review," *Case Reports in Medicine*, vol. 2022, p. 10, Article ID 6013523, 2022.
[2] K. S. Cheung, I. F. Hung, P. P. Chan et al., “Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis,” *Gastroenterology*, vol. 159, no. 1, pp. 81–95, 2020.
[3] S. H. Wong, R. N. Lui, and J. J. Sung, "Covid-19 and the digestive system," *Journal of Gastroenterology and Hepatology*, vol. 35, no. 5, pp. 744–748, 2020.
[4] E. de-Madaria and G. Capurso, "COVID-19 and acute pancreatitis: examining the causality," *Nature Reviews Gastroenterology & Hepatology*, vol. 18, no. 1, pp. 3–4, 2021.
[5] P. A. Banks, T. L. Bollen, C. Dervenis et al., "Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus," *Gut*, vol. 62, no. 1, pp. 102–111, 2013.
[6] P. F. Lawrence, *Essentials of General Surgery*, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2013.
[7] S. M. Van Dijk, N. D. L. Hallensleben, H. C. van Santvoort et al., "Acute pancreatitis: recent advances through randomised trials," *Gut*, vol. 66, no. 11, pp. 2024–2032, 2017.
[8] J. A. Müller, R. GroB, C. Conzelmann et al., "SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas," *Nature Metabolism*, vol. 3, no. 2, pp. 149–165, 2021.
[9] U. Abramczyk, M. Nowaczynski, A. Slomczynski, P. Wojnicz, P. Zatyka, and A. Kuzan, "Consequences of COVID-19 for the pancreas," *International Journal of Molecular Sciences*, vol. 23, no. 2, p. 864, 2022.
[10] M. K. Smatti, F. S. Cyprian, G. K. Nasrallah, A. A. Al Thani, R. O. Almishal, and H. M. Yassine, "Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms," *Viruses*, vol. 11, no. 8, p. 762, 2019.
[11] P. Hegyi, Z. Szakács, and M. Sahin-Tóth, "Lipotoxicity and cytokine storm in severe acute pancreatitis and COVID-19," *Gastroenterology*, vol. 159, no. 3, pp. 824–827, 2020.
[12] C. T. Esmon, "Reprint of Crosstalk between inflammation and thrombosis," *Maturitas*, vol. 61, no. 1-2, pp. 122–131, 2008.
[13] H. Basit, G. J. Ruan, and S. Mukherjee, "Ranson Criteria," *StatPearls Publishing*, Treasure Island, FL, USA, 2018.
[14] B. Rau, A. Paskowski, S. Lillich, K. Baumgart, P. Moller, and H. G. Beger, "Differential effects of caspase-1/interleukin-1β–converting enzyme on acinar cell necrosis and apoptosis in severe acute experimental pancreatitis," *Laboratory Investigation*, vol. 81, no. 7, pp. 1001–1013, 2001.
[15] Y. Tsuji, N. Takahashi, and C. Tsutomu, "Pancreatic perfusion CT in early stage of severe acute pancreatitis," *International Journal of Inflammation*, vol. 2012, pp. 1–5, 2012.
[16] A. Garber, C. Frakes, Z. Arora, and P. Chahal, "Mechanisms and management of acute pancreatitis," *Gastroenterology research and practice*, vol. 2018, pp. 1–8, 2018.
[17] Q. Zheng, L. Cao, H. Ma et al., “Evidence-based care can improve treatment compliance and quality of life of patients with acute pancreatitis,” *Journal of Healthcare Engineering*, vol. 2022, pp. 1–8, 2022.